Marcelo Kugelmas is a Gastroenterology physician affiliated with Catholic Health Initiatives. OpenAlex indexes 87 publications with 6,635 citations (h-index 27).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
499 E Hampden Ave
Ste 420
Englewood, CO 801132780
Telephone
303-788-8888Provider last certified this registry record 31 Oct 2023.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202533 payments$70,904openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202527 payments$46,081openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year202519 payments$32,126openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2004–2005 per NIH RePORTER. The latest:
- HEPATITIS C NOT RESPONSIVE TO INTERFERON W/ OR W/O RIBAV W/PEG-INT &REBET
University of Colorado Denver
FY2005$858M01RR000051 - Hepatitis C not Responsive to Interferon w/ Ribavirin
University of Colorado Denver
FY2004$19,893M01RR000051
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A global research priority agenda to advance public health responses to fatty liver disease
Journal of Hepatology
2023 - Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Journal of Hepatology
2023 - Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis
American Journal of Health-System Pharmacy
2023
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”